Comparative Pharmacology
Head-to-head clinical analysis: KALEXATE versus ZOLOFT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KALEXATE versus ZOLOFT.
KALEXATE vs ZOLOFT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KALEXATE is a monoclonal antibody that binds to both soluble and membrane-bound human interleukin-6 (IL-6) receptors, inhibiting IL-6-mediated signaling. IL-6 is a pro-inflammatory cytokine implicated in the pathogenesis of rheumatoid arthritis and other inflammatory conditions.
Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity in the CNS by blocking the reuptake of serotonin at the presynaptic neuronal membrane, resulting in increased serotonin concentrations in the synaptic cleft.
10 mg orally once daily.
50 mg orally once daily, increased by 50 mg increments at 1-week intervals up to 200 mg/day for depression, OCD, panic disorder, PTSD, PMDD, social anxiety disorder.
None Documented
None Documented
12-15 hours; prolonged in renal impairment (up to 30 hours in severe cases)
26 hours (terminal elimination half-life); steady state achieved in ~1 week; metabolite desmethylsertraline half-life 66 hours.
Primarily renal (75-80% as unchanged drug); biliary/fecal (15-20%)
Renal: <0.5% unchanged; extensive hepatic metabolism; metabolites excreted renally and fecally.
Category C
Category C
SSRI Antidepressant
SSRI Antidepressant